Market by Mechanism, Indicator, Consumer, Commodity, and Country Outlook | Forecast 2022-2028
According to Triton’s research report, the companion diagnostics market in Latin America is estimated to advance with a CAGR of 12.10% over the forecasted period 2022-2028.
Report scope can be customized per your requirements. Request For CustomizationÂ
The countries examined in the given region are:
•       Â
Brazil
•       Â
Mexico
•        Rest
of Latin America
In Latin America, Brazil captures the largest
share in the studied market. The region has witnessed robust growth in precision
medicine technology, owing to various initiatives to promote R&D. In this
regard, pharmaceutical companies, diagnostics firms, and service providers are
collaborating to facilitate access to precision medicine technologies. Further,
the improvement in public-private partnerships has resulted in easy access to
hospitals in small cities. Such developments are facilitating the expansion of
companion diagnostics technology across the region to a large extent.
The Ministry of Health formulated a campaign to
advance Brazil’s companion diagnostics sector, enhancing access to high-quality
molecular testing. This has resulted in various partnerships among government,
regulatory agencies, pharmaceutical companies, and academic institutes to
support CDx technology.
Furthermore, Brazil’s dominance over the market is
expected to continue over the next few years, owing to the rising focus on
precision medicine. For instance, the Brazilian initiatives on precision
medicine offer a platform that permits sharing of genetic and clinical data.
Thus, as mentioned above, these factors support the companion diagnostics market’s
growth.
The rise in cancer cases globally is expected to boost
the adoption of companion diagnostics devices. In this regard, these devices
are used to develop accurate medicine for specific cancer cases. Besides this,
the advanced drugs developed using companion diagnostics devices enable precise
treatment and quick recovery. The studied
market’s growth is examined in terms of indicator, consumer, commodity, and
mechanism. The indicator section includes oncology, infectious diseases,
neurology, and other indicators.
The leading companies in the market consist of
Illumina Inc, Qiagen, Sysmex Corporation, Thermo Fisher Scientific, Agilent,
and Roche Diagnostics.
Sysmex
Corporation designs, manufactures, and markets diagnostics devices, reagents,
and related software for immunochemistry, hematology, urinalysis, clinical
chemistry, and hemostasis. The company offers systems for high-volume testing
in labs and blood cell differentiation for hematology applications. Besides
this, the company provides automated equipment systems. Sysmex serves numerous
clients, including private hospitals, universities, research institutes, and
public hospitals.
Â
Key deliverables of the report:
·      Market CAGR during the forecasting
years 2022-2028
·      Detailed data highlighting key
insights, industry components, and market strategies
·   Comprehensive information and
estimation of the companion diagnostics market revenue growth in Latin America
and its influence on the parent market
·      In-depth study of forthcoming trends
in consumer behavioral patterns
·      A meticulous analysis of the
competitive landscape, vendor scorecard, and Porter’s Five Forces
·  A wide-ranging study of factors that
will challenge the LA companion diagnostics market’s growth during the upcoming
years
Want to get specific insights? Our team of analysts
can customize this report based on your preferences. Connect with us here.Â
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. LATIN
AMERICA COMPANION DIAGNOSTICS MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET
2.2. KEY
INSIGHTS
2.2.1. COMMERCIAL
SUCCESS OF PRECISION MEDICINE TREATMENT
2.2.2. ADOPTION
OF PREDICTIVE BIOMARKERS
2.2.3. FUSION
OF COMPUTER SCIENCE AND BIOLOGY
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. KEY
BUYING IMPACT ANALYSIS
2.4.1. COST
2.4.2. AVAILABILITY
2.4.3. SENSITIVITY
& SPECIFICITY
2.4.4. EFFICACY
2.5. MARKET
ATTRACTIVENESS INDEX
2.6. VENDOR
SCORECARD
2.7. INDUSTRY
COMPONENTS
2.8. REGULATORY
FRAMEWORK
2.9. KEY
MARKET STRATEGIES
2.9.1. ACQUISITIONS
2.9.2. PRODUCT
LAUNCHES
2.9.3. CONTRACTS
& AGREEMENTS
2.10. MARKET
DRIVERS
2.10.1. INCREASE
IN INCIDENCE OF MEDICATION REACTIONS
2.10.2. INCREASING
PREVALENCE OF CANCER CASES AND FATALITIES
2.10.3. RISING
PREVALENCE OF PRECISION MEDICINES
2.11. MARKET
CHALLENGES
2.11.1. WEAK
REIMBURSEMENT FRAMEWORK
2.11.2. COMMON
CASES OF LEAKAGE IN ONCOLOGY COMPANION DIAGNOSTICS
2.12. MARKET
OPPORTUNITY
2.12.1. ONGOING
RESEARCH AND INVESTMENTS IN NEXT GENERATION GENE-SEQUENCING
3. LATIN
AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK - BY MECHANISM
3.1. IN-SITU
HYBRIDIZATION
3.2. POLYMERASE
CHAIN REACTION
3.3. IMMUNOHISTOCHEMISTRY
3.4. NEXT
GENERATION SEQUENCING
3.5. OTHER
MECHANISMS
4. LATIN
AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK - BY INDICATOR
4.1. ONCOLOGY
4.2. NEUROLOGY
4.3. INFECTIOUS
DISEASES
4.4. OTHER
INDICATORS
5. LATIN
AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK - BY CONSUMER
5.1. PHARMACEUTICAL
AND BIOPHARMACEUTICAL COMPANIES
5.2. REFERENCE
LABORATORIES
5.3. OTHER
CONSUMERS
6. LATIN
AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK - BY COMMODITY
6.1. ASSAY
KITS AND REAGENTS
6.2. SOFTWARE
AND SERVICES
7. LATIN AMERICA
COMPANION DIAGNOSTICS MARKET - COUNTRY OUTLOOK
7.1. BRAZIL
7.2. MEXICO
7.3. REST
OF LATIN AMERICA
8. COMPETITIVE
LANDSCAPE
8.1. ABBOTT
LABORATORIES
8.2. ALMAC
GROUP
8.3. ARUP
LABORATORIES
8.4. BIOCARTIS
8.5. BIOMERIEUX
8.6. DANAHER
CORPORATION
8.7. GE
HEALTHCARE
8.8. GENOMIC
HEALTH
8.9. ILLUMINA
INC
8.10. MYRIAD
GENETICS
8.11. QIAGEN
8.12. ROCHE
DIAGNOSTICS
8.13. SYSMEX
CORPORATION
8.14. THERMO
FISHER SCIENTIFIC
8.15. AGILENT
9. RESEARCH
METHODOLOGY & SCOPE
9.1. RESEARCH
SCOPE & DELIVERABLES
9.2. SOURCES
OF DATA
9.3. RESEARCH
METHODOLOGY
TABLE 1: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF PRODUCT
LAUNCHES
TABLE 5: LIST OF CONTRACTS
& AGREEMENTS
TABLE 6: NUMBER OF CANCER
PATIENTS IN 2020
TABLE 7: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 8: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 9: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 10: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 11: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
FIGURE 1: MARKET
ATTRACTIVENESS INDEX
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: FDA FRAMEWORK
FIGURE 4: CDX LEAKAGE POINTS
FIGURE 5: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2021 & 2028 (IN %)
FIGURE 6: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, BY IN-SITU HYBRIDIZATION, 2022-2028 (IN $
MILLION)
FIGURE 7: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2028 (IN $
MILLION)
FIGURE 8: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, BY IMMUNOHISTOCHEMISTRY, 2022-2028 (IN $ MILLION)
FIGURE 9: LATIN AMERICA COMPANION
DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2028 (IN $ MILLION)
FIGURE 10: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, BY OTHER MECHANISMS, 2022-2028 (IN $ MILLION)
FIGURE 11: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2021 & 2028 (IN %)
FIGURE 12: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2028 (IN $ MILLION)
FIGURE 13: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2028 (IN $ MILLION)
FIGURE 14: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2028 (IN $ MILLION)
FIGURE 15: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATORS, 2022-2028 (IN $ MILLION)
FIGURE 16: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2021 & 2028 (IN %)
FIGURE 17: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL
COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 18: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2028 (IN $
MILLION)
FIGURE 19: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, BY OTHER CONSUMERS, 2022-2028 (IN $ MILLION)
FIGURE 20: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2021 & 2028 (IN %)
FIGURE 21: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2028 (IN $
MILLION)
FIGURE 22: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, BY SOFTWARE AND SERVICES, 2022-2028 (IN $
MILLION)
FIGURE 23: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 24: BRAZIL COMPANION
DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 25: MEXICO COMPANION
DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 26: REST OF LATIN
AMERICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)